Full Year 2023 Investor Presentation
9
Investor presentation
Full year 2023
Obesity care sales grew by 154% in 2023 mainly driven by the
US
NN sales and volume BAOM market growth
within Obesity care
DKK billion
55%¹
15
12
9
16
3
Branded AOM TRX in the US²
TRX count ('000s)
84%1
154%1
160
120%
116%
95%
120
147
70%
92
80
45%
40
20%
37
Novo NordiskⓇ
ONCE-WEEKLY
wegovy
semaglutide injection 2.4 mg
The US
•
The supply of the lower dose
strengths has been restricted since
May 2023 to safeguard continuity of
care
Novo Nordisk started gradually
increasing the supply of the lower
dose strengths in January 2024
International Operations
WegovyⓇ launched in Denmark,
Norway, Germany, UK, Switzerland
Iceland and UAE
Continued volume capped launches
in IO in 2024, balancing supply and
demand
0
-5%
0
2021
2022
2023
June
2021
IO INAO
-
- BAOM Market growth (RHS)
Saxenda Ⓡ
INN sales growth at CER
Branded AOM market
-
1 Annual growth at CER. Each TRx data points represents one week of data; 2 IQVIA weekly, 19 Jan 2024
4
January
2024
• WegovyⓇ
tirzepatide
CER: Constant exchange rates; NAO: North America operations; IO: International operations; RHS: Right-hand side axis; TRX: Total Prescriptions; AOM: Anti-Obesity Medications (includes Wegovy®, Saxenda®, Zepbound, Qsymia, Belviq and Contrave); BAOM:
Branded AOM market; UAE: United Arab Emirates. Note: Sales growth at constant exchange rates. 116% volume growth for Global BAOM market growth refers to moving annual total.View entire presentation